CA3153099A1 — Methods of treating epileptic patients with fenfluramine
Assigned to Zogenix International Ltd · Expires 2021-03-25 · 5y expired
What this patent protects
The present disclosure provides methods of treating and/or preventing symptoms of epilepsy or epileptic encephalopathy where fenfluramine or a pharmaceutically acceptable salt thereof is or has been administered to a patient or population of patients. The present disclosure encom…
USPTO Abstract
The present disclosure provides methods of treating and/or preventing symptoms of epilepsy or epileptic encephalopathy where fenfluramine or a pharmaceutically acceptable salt thereof is or has been administered to a patient or population of patients. The present disclosure encompasses a recognition of contraindication of fenfluramine and certain serotonin receptor agonists, particularly a CNS penetrant serotonin receptor antagonist. The present disclosure provides methods where said patients being administered fenfluramine have been warned against co-administration of certain serotonin receptor antagonists, are not co-administered a serotonin receptor antagonist, and/or in which co-administration of a serotonin-receptor antagonist is discontinued.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.